Showing 8051-8060 of 9881 results for "".
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disord
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Nutrafol May Promote Hair Growth in Menopausal Womenhttps://practicaldermatology.com/news/nutrafol-may-promote-hair-growth-in-menopausal-women/2460923/Nutrafol may improve hair growth and quality for perimenopausal, menopausal, and postmenopausal women, according to research presented during The North American Menopause Society (NAMS) Annual Meeting in Washington, DC. Researchers compared results at 6 mont
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- New Global Initiative Aims to Improve Eczema Carehttps://practicaldermatology.com/news/new-global-initiative-aims-to-improve-eczema-care/2460913/The new Global Patient Initiative to Improve Eczema Care (GPIIEC) is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients with eczema and their caregivers. The global
- NPF Task Force Issues New Guidance on COVID-19 Vaccine Boosters for PsO Patientshttps://practicaldermatology.com/news/npf-task-force-issues-new-guidance-on-covid-19-vaccine-boosters-for-pso-patients/2460911/The Centers for Disease Control and Prevention (CDC) recently released new information on COVID-19 vaccines for moderately to severely immunocompromised people. Since these individuals may be especially vulnerable to COVID-19, due to their increased
- Registration Open for ISHRS Hybrid World Congresshttps://practicaldermatology.com/news/registration-open-for-ishrs-hybrid-world-congress/2460902/The 29th Meeting of the International Society of Hair Restoration Surgery (ISHRS) is coming October 21-23. Registration is now open for the Hybrid World Congress 2021, with the i
- Landmarks and Bridges Go Blue for Alopecia Areata Awareness Monthhttps://practicaldermatology.com/news/landmarks-and-bridges-go-blue-for-alopecia-areata-awareness-month/2460900/Bridges, buildings and other landmarks across the United States will be illuminated blue in recognition of Alopecia Areata Awareness Month this September, The current illumination schedule follows below. Any updates or additions to the schedule will be posted
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the <
- FDA Approves Amendment to Avita's Vitiligo Trial Designhttps://practicaldermatology.com/news/fda-approves-amendment-to-avitas-vitiligo-trial-design/2460893/Avita Medical, Inc. will move forward with an amended pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design, now that the FDA has approved the trial modification. The